Metabolic acetate therapy improves phenotype in the tremor rat model of Canavan disease.
Genetic mutations that severely diminish the activity of aspartoacylase (ASPA) result in the fatal brain dysmyelinating disorder, Canavan disease. There is no effective treatment. ASPA produces free acetate from the concentrated brain metabolite, N-acetylaspartate (NAA). Because acetyl coenzyme A is a key building block for lipid synthesis, we postulated that the inability to catabolize NAA leads to a brain acetate deficiency during a critical period of CNS development, impairing myelination and possibly other aspects of brain development. We tested the hypothesis that acetate supplementation during postnatal myelination would ameliorate the severe phenotype associated with ASPA deficiency using the tremor rat model of Canavan disease. Glyceryltriacetate (GTA) was administered orally to tremor rats starting 7 days after birth, and was continued in food and water after weaning. Motor function, myelin lipids, and brain vacuolation were analyzed in GTA-treated and untreated tremor rats. Significant improvements were observed in motor performance and myelin galactocerebroside content in tremor rats treated with GTA. Further, brain vacuolation was modestly reduced, and these reductions were positively correlated with improved motor performance. We also examined the expression of the acetyl coenzyme A synthesizing enzyme acetyl coenzyme A synthase 1 and found upregulation of expression in tremor rats, with a return to near normal expression levels in GTA-treated tremor rats. These results confirm the critical role played by NAA-derived acetate in brain myelination and development, and demonstrate the potential usefulness of acetate therapy for the treatment of Canavan disease.
Arun
Peethambaran
P
Department of Anatomy, Physiology and Genetics, Neuroscience Program and Molecular and Cell Biology Program, Uniformed Services University of the Health Sciences, Building C, Bethesda, MD 20814, USA.
Madhavarao
Chikkathur N
CN
Moffett
John R
JR
Hamilton
Kristen
K
Grunberg
Neil E
NE
Ariyannur
Prasanth S
PS
Gahl
William A
WA
Anikster
Yair
Y
Mog
Steven
S
Hallows
William C
WC
Denu
John M
JM
Namboodiri
Aryan M A
AM
D000085:Acetates / Q000627:therapeutic use*; D000818:Animals; D001224:Aspartic Acid / Q000031:analogs & derivatives* / Q000378:metabolism / Q000627:therapeutic use; D001921:Brain / Q000378:metabolism; D017825:Canavan Disease / Q000628:therapy*; D004195:Disease Models, Animal; D005260:Female; D006579:Heterozygote; D008055:Lipids / Q000737:chemistry; D008297:Male; D009154:Mutation; D009186:Myelin Sheath / Q000737:chemistry; D010641:Phenotype; D051381:Rats; D016896:Treatment Outcome
D000085:Acetates; D008055:Lipids; D001224:Aspartic Acid; C000179:N-acetylaspartate
Proc Natl Acad Sci U S A. 2006 Jul 5;103(27):10230-10235
16790548
Proc Natl Acad Sci U S A. 2005 Apr 5;102(14):5221-6
15784740
J Neurochem. 2001 Aug;78(4):736-45
11520894
Biochem J. 1980 Apr 15;188(1):163-8
7406877
Neurobiol Dis. 2005 Mar;18(2):385-9
15686967
Mol Ther. 2005 May;11(5):745-53
15851013
J Gene Med. 2000 May-Jun;2(3):165-75
10894262
Int J Biochem Cell Biol. 2009 Jan;41(1):185-98
18804549
Glia. 2009 Nov 15;57(15):1579-87
19373939
Prog Neurobiol. 2009 Jul;88(3):170-83
19554713
Hum Pathol. 1973 Sep;4(3):331-47
4593851
J Neurotrauma. 2010 Jan;27(1):293-8
19803785
J Mol Neurosci. 2003;21(3):185-90
14645985
Biochem J. 2007 Nov 1;407(3):383-95
17425515
J Neurochem. 1966 Oct;13(10):961-5
5927765
Clin Chim Acta. 1986 Aug 15;158(3):217-27
3769199
J Neurosci. 2008 Nov 5;28(45):11537-49
18987190
Ann Neurol. 2000 Jul;48(1):27-38
10894213
J Comp Neurol. 2004 May 3;472(3):318-29
15065127
J Comp Neurol. 2010 Aug 1;518(15):2952-77
20533355
Nat Neurosci. 2009 Jul;12(7):829-38
19503085
J Pharmacol Exp Ther. 2005 Oct;315(1):297-303
16002461
Am J Med Genet. 1988 Feb;29(2):463-71
3354621
Drug Metab Dispos. 2007 Jul;35(7):1203-8
17452418
FASEB J. 2006 Oct;20(12):2139-41
16935940
Prog Neurobiol. 2007 Feb;81(2):89-131
17275978
J Nutr. 1992 Sep;122(9):1823-9
1512631
Hum Gene Ther. 2002 Jul 20;13(11):1391-412
12162821
Exp Brain Res. 1968;5(4):267-73
5712694
Nat Neurosci. 2009 Apr;12(4):379-85
19287390
Brain Res Mol Brain Res. 2005 Apr 27;135(1-2):112-21
15857674
JPEN J Parenter Enteral Nutr. 1991 Jan-Feb;15(1):32-6
1901105
J Biol Chem. 2000 Aug 25;275(34):26458-66
10843999
Science. 2009 May 22;324(5930):1076-80
19461003
Neuroreport. 2003 Oct 6;14(14):1837-40
14534431
J Inherit Metab Dis. 1999 Apr;22(2):99-101
10234603
Pharmacol Biochem Behav. 2004 Jan;77(1):21-8
14724038
Biochem J. 1979 Dec 15;184(3):539-46
540047
J Inherit Metab Dis. 2009 Oct;32(5):640
19685155
J Neurochem. 2000 Jun;74(6):2512-9
10820213
J Neurosci Res. 2009 Nov 15;87(15):3415-27
19739253
Neurochem Res. 2009 Jan;34(1):138-48
18478328
J Neurochem. 1973 Oct;21(4):749-57
4271082